A new trial sponsored by Axial Therapeutics will test whether a medication that targets gut bacteria can also improve...
Read more
Axial Therapeutics announced that A. Stewart Campbell, Ph.D., chief executive officer, will give a presentation titled, “Targeting Bacterial Metabolites...
Read more
Axial Therapeutics announced that it is building on its clinical development science and operations capabilities through recent key appointments....
Read more
Axial Therapeutics Inc. announced that A. Stewart Campbell, Ph.D., Chief Executive Officer, will present in two seminars at BioJapan...
Read more
Axial Therapeutics announced that A. Stewart Campbell, Ph.D., will participate in a panel entitled “The Next Wave of Targeted...
Read more
Seed Health and Axial Therapeutics announced a joint development program targeting the microbiome-gut-brain axis for mental health, with the potential...
Read more
Axial Therapeutics announced that A. Stewart Campbell, Ph.D., chief executive officer, will participate in a panel titled “Placing Patients...
Read more
Axial Therapeutics announced that its scientific founder and California Institute of Technology (Caltech) Professor, Sarkis Mazmanian, Ph.D., will be...
Read more
Axial Therapeutics announced the publication of preclinical research demonstrating that microbial metabolites produced by gut bacteria commonly found in...
Read more
Axial Therapeutics announced the publication in Nature Medicine of full results from its Phase 1b/2a clinical trial of AB-2004....
Read more